A senate committee must act next: committee consideration.
Legislative Progress
Senate
House
President
Law
Could go either way
The bill has strong bipartisan support from prominent senators, but it is currently a reporting requirement that must still clear the committee process.
Key Points
This bill requires the Federal Trade Commission to study how foreign money affects the American drug industry. It focuses on whether relying on other countries for medicine makes the U.S. supply chain weaker.
The government would look at how foreign investments impact our ability to make medicine at home. This includes looking at the raw ingredients used to create drugs and the factories that produce them.
The plan also tracks foreign investment in DNA technology. Officials want to know if foreign companies are gaining control over how Americans' genetic information is stored or analyzed.
Every year, the agency would release a public summary of its findings. This would show which foreign deals were reviewed and if the government blocked any of them for safety reasons.
Impact Analysis
Govbase has not yet run an impact analysis on this legislation.
Milestones
2 milestones2 actions
Jul 15, 2026Senate
Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Jul 15, 2026
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
No votes, news coverage, or related bills recorded for this bill yet.
Source Information
Document Type
Congressional Bill
Official Title
Pharmaceutical Investment Oversight and Accountability Act
Bill NumberS 4987
Congress119th Congress
ChamberSenate
Latest ActionRead twice and referred to the Committee on Banking, Housing, and Urban Affairs.
